Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.16
ENDP's Cash to Debt is ranked lower than
52% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ENDP: 0.16 )
ENDP' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.16

Equity to Asset 0.24
ENDP's Equity to Asset is ranked lower than
51% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ENDP: 0.24 )
ENDP' s 10-Year Equity to Asset Range
Min: 0.08   Max: 0.77
Current: 0.24

0.08
0.77
F-Score: 4
Z-Score: 0.60
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -58.48
ENDP's Operating margin (%) is ranked higher than
52% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. ENDP: -58.48 )
ENDP' s 10-Year Operating margin (%) Range
Min: -19.18   Max: 38.19
Current: -58.48

-19.18
38.19
Net-margin (%) -54.23
ENDP's Net-margin (%) is ranked higher than
52% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. ENDP: -54.23 )
ENDP' s 10-Year Net-margin (%) Range
Min: -79.44   Max: 24.67
Current: -54.23

-79.44
24.67
ROE (%) -71.70
ENDP's ROE (%) is ranked higher than
50% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. ENDP: -71.70 )
ENDP' s 10-Year ROE (%) Range
Min: -113.34   Max: 26.98
Current: -71.7

-113.34
26.98
ROA (%) -16.75
ENDP's ROA (%) is ranked higher than
55% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. ENDP: -16.75 )
ENDP' s 10-Year ROA (%) Range
Min: -39.34   Max: 17.45
Current: -16.75

-39.34
17.45
ROC (Joel Greenblatt) (%) -231.40
ENDP's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. ENDP: -231.40 )
ENDP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -116.32   Max: 753.26
Current: -231.4

-116.32
753.26
Revenue Growth (3Y)(%) 16.70
ENDP's Revenue Growth (3Y)(%) is ranked higher than
84% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ENDP: 16.70 )
ENDP' s 10-Year Revenue Growth (3Y)(%) Range
Min: 14.7   Max: 30.3
Current: 16.7

14.7
30.3
» ENDP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ENDP Guru Trades in Q4 2013

David Dreman 1,378 sh (New)
Steve Mandel 4,340,000 sh (New)
Wallace Weitz 445,920 sh (New)
Jim Simons 1,005,693 sh (+294.48%)
Jeremy Grantham 53,382 sh (+205.91%)
Steven Cohen 17,467 sh (+133.48%)
John Griffin 8,000,000 sh (+14.29%)
Stanley Druckenmiller 527,000 sh (unchged)
Andreas Halvorsen Sold Out
Richard Snow Sold Out
Ray Dalio 13,272 sh (-7.01%)
Mario Gabelli 33,350 sh (-18.76%)
Joel Greenblatt 397,016 sh (-23.94%)
» More
Q1 2014

ENDP Guru Trades in Q1 2014

Paul Tudor Jones 3,506 sh (New)
Julian Robertson 22,800 sh (New)
Louis Moore Bacon 5,602 sh (New)
Larry Robbins 1,964,201 sh (New)
George Soros 198,503 sh (New)
Steven Cohen 271,917 sh (+1456.75%)
Wallace Weitz 500,920 sh (+12.33%)
John Griffin 676,600 sh (unchged)
John Griffin 8,000,000 sh (unchged)
Stanley Druckenmiller Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
David Dreman Sold Out
Jeremy Grantham Sold Out
Steve Mandel 4,178,703 sh (-3.72%)
Mario Gabelli 30,550 sh (-8.4%)
Jim Simons 49,493 sh (-95.08%)
» More
Q2 2014

ENDP Guru Trades in Q2 2014

Joel Greenblatt 88,697 sh (New)
Chuck Royce 1,300 sh (New)
Paul Tudor Jones 177,373 sh (+4959.13%)
Louis Moore Bacon 15,334 sh (+173.72%)
Larry Robbins 3,930,472 sh (+100.11%)
Wallace Weitz 876,670 sh (+75.01%)
John Griffin 6,766 sh (unchged)
Julian Robertson 22,800 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Steve Mandel Sold Out
John Griffin 6,815,000 sh (-14.81%)
Mario Gabelli 23,900 sh (-21.77%)
» More
Q3 2014

ENDP Guru Trades in Q3 2014

Larry Robbins 5,658,326 sh (+43.96%)
John Griffin 676,600 sh (unchged)
Louis Moore Bacon Sold Out
Chuck Royce Sold Out
Mario Gabelli 22,900 sh (-4.18%)
Julian Robertson 20,300 sh (-10.96%)
John Griffin 5,698,528 sh (-16.38%)
Wallace Weitz 721,950 sh (-17.65%)
Joel Greenblatt 13,716 sh (-84.54%)
Paul Tudor Jones 19,281 sh (-89.13%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Griffin 2014-09-30 Reduce -16.38%0.77%$61.26 - $70.27 $ 7311%5698528
Wallace Weitz 2014-09-30 Reduce -17.65%0.34%$61.26 - $70.27 $ 7311%721950
Joel Greenblatt 2014-09-30 Reduce -84.54%0.07%$61.26 - $70.27 $ 7311%13716
Steve Mandel 2014-06-30 Sold Out 1.2%$56.28 - $73.94 $ 739%0
John Griffin 2014-06-30 Reduce -14.81%0.9%$56.28 - $73.94 $ 739%6815000
Wallace Weitz 2014-06-30 Add 75.01%0.81%$56.28 - $73.94 $ 739%876670
George Soros 2014-06-30 Sold Out 0.13%$56.28 - $73.94 $ 739%0
Joel Greenblatt 2014-06-30 New Buy0.08%$56.28 - $73.94 $ 739%88697
Mario Gabelli 2014-06-30 Reduce -21.77%$56.28 - $73.94 $ 739%23900
Joel Greenblatt 2014-03-31 Sold Out 0.64%$64.3 - $81.49 $ 733%0
Julian Robertson 2014-03-31 New Buy0.51%$64.3 - $81.49 $ 733%22800
George Soros 2014-03-31 New Buy0.13%$64.3 - $81.49 $ 733%198503
Wallace Weitz 2014-03-31 Add 12.33%0.12%$64.3 - $81.49 $ 733%500920
Ray Dalio 2014-03-31 Sold Out 0.01%$64.3 - $81.49 $ 733%0
David Dreman 2014-03-31 Sold Out 0.01%$64.3 - $81.49 $ 733%0
Steve Mandel 2013-12-31 New Buy1.3%$43.64 - $67.25 $ 7328%4340000
Wallace Weitz 2013-12-31 New Buy1%$43.64 - $67.25 $ 7328%445920
Andreas Halvorsen 2013-12-31 Sold Out 0.81%$43.64 - $67.25 $ 7328%0
John Griffin 2013-12-31 Add 14.29%0.7%$43.64 - $67.25 $ 7328%8000000
Joel Greenblatt 2013-12-31 Reduce -23.94%0.18%$43.64 - $67.25 $ 7328%397016
Richard Snow 2013-12-31 Sold Out 0.12%$43.64 - $67.25 $ 7328%0
David Dreman 2013-12-31 New Buy0.01%$43.64 - $67.25 $ 7328%1378
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Endo International PLC

Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector
During the campaigns in the recently concluded midterm elections, incumbent Democrats were reluctant to speak of Obamacare, almost as hesitant as they were to be seen with the president, on the campaign trail. Read more...

Ratios

vs
industry
vs
history
P/B 4.50
ENDP's P/B is ranked higher than
67% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. ENDP: 4.50 )
ENDP' s 10-Year P/B Range
Min: 1.48   Max: 17.5
Current: 4.5

1.48
17.5
P/S 3.76
ENDP's P/S is ranked higher than
74% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. ENDP: 3.76 )
ENDP' s 10-Year P/S Range
Min: 1.03   Max: 6.1
Current: 3.76

1.03
6.1
PFCF 135.19
ENDP's PFCF is ranked higher than
80% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ENDP: 135.19 )
ENDP' s 10-Year PFCF Range
Min: 4.6   Max: 264.07
Current: 135.19

4.6
264.07
EV-to-EBIT -9.58
ENDP's EV-to-EBIT is ranked higher than
58% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. ENDP: -9.58 )
ENDP' s 10-Year EV-to-EBIT Range
Min: -29.3   Max: 27.3
Current: -9.58

-29.3
27.3
Current Ratio 1.32
ENDP's Current Ratio is ranked higher than
55% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. ENDP: 1.32 )
ENDP' s 10-Year Current Ratio Range
Min: 1.22   Max: 3.55
Current: 1.32

1.22
3.55
Quick Ratio 1.09
ENDP's Quick Ratio is ranked higher than
58% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ENDP: 1.09 )
ENDP' s 10-Year Quick Ratio Range
Min: 0.97   Max: 3.34
Current: 1.09

0.97
3.34

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.59
ENDP's Price/DCF (Projected) is ranked higher than
90% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. ENDP: 1.59 )
ENDP' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 1.97
Current: 1.59

0.4
1.97
Price/Median PS Value 1.35
ENDP's Price/Median PS Value is ranked higher than
71% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. ENDP: 1.35 )
ENDP' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 2.93
Current: 1.35

0.39
2.93
Earnings Yield (Greenblatt) -10.40
ENDP's Earnings Yield (Greenblatt) is ranked higher than
51% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ENDP: -10.40 )
ENDP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.7   Max: 25.4
Current: -10.4

3.7
25.4
Forward Rate of Return (Yacktman) 18.82
ENDP's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. ENDP: 18.82 )
ENDP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 63.3
Current: 18.82

3.3
63.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EO7.Germany, ENL.Canada,
Endo International PLC was formed on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. Its current portfolio is associated with a set of therapeutic areas including, Allergy Immunotherapy, Central Precocious Puberty, Dermatology, Insomnia, Pain, Pelvic Health, Urology and Women's Health.
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector Dec 01 2014 
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
H/C -- winner. Down Mar 02 2013 
greenblatt - low Jan 22 2013 
comment on ENDP Nov 28 2012 
comment on ENDP Jul 09 2012 
Weekly Top Insider Buys: MDT, KMI, WIN, ENDP, OC Jun 25 2012 
Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP Jun 16 2012 
Endo Pharmaceuticals Holdings Inc. (ENDP) EVP, CFO Alan G Levin sells 16,627 Shares Dec 09 2010 
Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q) Nov 02 2010 


More From Other Websites
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal Gel Dec 09 2014
Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal Gel Dec 09 2014
Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal Gel Dec 09 2014
ENDO INTERNATIONAL PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 03 2014
Trimel Announces Exclusive License Agreement With Endo For Natesto™ Nov 24 2014
Endo Acquires Rights to Natesto™ Testosterone Nasal Gel Nov 24 2014
Endo Acquires Rights to Natesto™ Testosterone Nasal Gel Nov 24 2014
Endo Acquires Rights to Natesto™ Testosterone Nasal Gel Nov 24 2014
U.S. court denies Ranbaxy's bid to block launch of rival generics Nov 20 2014
U.S. court denies Ranbaxy's bid to block launch of rival generics Nov 20 2014
U.S. court denies Ranbaxy's bid to block launch of rival generics Nov 20 2014
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 20 2014
Endo Announces Launch of Generic Version of Valcyte® Nov 20 2014
Endo Announces Launch of Generic Version of Valcyte® Nov 20 2014
U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs Nov 20 2014
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 19 2014
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK